Background: When gastro-oesophageal reflux is causing symptoms or lesions in the oesophagus, this is referred to as gastro-oesophageal reflux disease (GERD). GERD can manifest itself through typical symptoms (heartburn, regurgitation) or may lead to extra-oesophageal symptoms. Extra-oesophageal manifestations of GERD gained increasing attention over the last decade, especially respiratory disorders, because of the prevalent co-occurrence with GERD. The role of GERD in the pathogenesis of respiratory disorders has become a topic of intense discussion.
| INTRODUCTION
Gastro-oesophageal reflux (GER) is the retrograde bolus movement of gastric content into the oesophagus, which is a physiological phenomenon. When GER is causing troublesome symptoms and/or lesions in the oesophagus, it is referred to as gastro-oesophageal reflux disease (GERD). 1 The prevalence of GERD is increasing, with
Western Europe, North and South America having the highest prevalence rates ranging from 20% to 40%. [2] [3] [4] [5] GERD can manifest itself through a number of typical symptoms, eg, heartburn and regurgitation. However, reflux of acid, pepsin and bile acids may have broader effects than these well-established oesophageal manifestations;
GERD may also lead to so-called extra-oesophageal symptoms.
Over the last decades, these atypical manifestations or extraoesophageal syndromes (EOS) of GERD gained increasing attention, both in a clinical setting and in the medical literature, and the role of GERD in the pathogenesis of various respiratory disorders has become a topic of intense discussion. An association between GERD and respiratory disorders was first described in 1966, implicating GERD in the pathophysiology of asthma. 6 Results of the large European ProGERD study showed that 4.8% of GERD patients may have asthma. 7 A similar study in North America showed that asthma (9.3%) is the third most common EOS. 8 The degree of oesophageal mucosal injury and severity of GERD-related symptoms is predominantly determined by the degree and duration of oesophageal acid exposure, which largely depends on failure of protective mechanisms. First, the lower and upper oesophageal sphincter (LOS and UOS) protect the pharyngeal and laryngeal spaces from refluxate. Second, the oesophago-glottic closure reflex protects the airway from contact with the refluxate. 9, 10 In addition, both swallow-induced or primary peristalsis and secondary peristalsis are essential mechanisms of oesophageal clearance.
In case of reflux, oesophageal peristalsis produces volume clearance and allows swallowed saliva to reach the distal oesophagus to neutralise acid. 11 Primary peristalsis seems to be mainly present when subjects are upright and awake. Since sleep inhibits swallowing, secondary peristalsis is more important during night-time. [12] [13] [14] Disruption of any of these protective mechanisms could possibly contribute to the pathophysiology underlying EOS.
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| Diagnosis of GERD
The presence of GER can be measured through a number of different ways, and establishing the diagnosis of EOS of reflux is challenging due to the lack of gold standard diagnostic criteria. 21 GER can be quantified by questioning symptom frequency and symptom severity. 22 Several questionnaires can be applied, however, the disadvantages of a questionnaire-based strategy are the subjectivity and the absence of established cut-off points. 23 Ambulatory oesophageal pH-or impedance-pH monitoring is the gold standard to quantify GER. Combined multichannel intraluminal impedance and pH-monitoring detects not only both acid and nonacid reflux but also provides additional information concerning the composition of the refluxate (liquid, gas or mixed). 24, 25 However, particularly in the case of EOS, the diagnostic accuracy of this technique is rather modest. 26 , 27 Vaezi et al demonstrated that the reproducibility of the proximal pH probe in detecting acid reflux into the proximal part of the oesophagus was only 55% in patients with proximal oesophageal acid reflux. These results made the authors conclude that a negative test result does not exclude proximal reflux with possible micro-aspiration as a cause of atypical reflux symptoms. 26 Furthermore, thresholds used on pH or pH-impedance monitoring to define GERD are not always consistent, as has been recently demonstrated by Roman et al. 28 Upper endoscopy is an excellent tool to evaluate potential reflux consequences, since it has the advantage of providing luminal and objective assessments of the presence of GERD lesions; unfortunately a large proportion of GERD patients have no macroscopic lesions, and this method does not allow to distinguish microscopic changes in oesophageal mucosa that may be the underlying cause of symptoms in some individuals. Dilated intercellular spaces (DIS), an early morphologic marker in GERD reflecting the alteration of oesophageal mucosal integrity, 29 is not visible on routine endoscopy. Bredenoord et al concluded that endoscopy is a test with high specificity but low sensitivity for GERD diagnosis. 25 Empirical PPI use can be useful since resolution of symptoms may render additional diagnostic testing unnecessary. 25, 30 Nevertheless, a favourable response to high dosages of PPIs is not specific and does not confidently diagnose GERD. 30 Finally, investigating the presence of salivary pepsin in patients with symptoms suggestive of GERD, may reduce the use of unnecessary anti-reflux therapy and the need for further diagnostic methods. However, Sifrim et al demonstrated a substantial overlap between healthy controls and GERD patients, which is a major disadvantage of this test. 31 The aim of this review was to provide an overview of the role of GERD in asthma and chronic obstructive pulmonary disease (COPD).
According to the Montreal classification, asthma is considered a well-established association of GERD, 1 and although the association of GERD and COPD remains relatively unclear, there are strong indications of a relationship between GERD and COPD exacerbations.
| METHODS
The scientific database PubMed was searched for relevant full text articles using the keywords: GERD, asthma, COPD, prevalence, treat- | 177 this review case reports were excluded, and only English language publications were considered.
| PART I: Asthma
The American thoracic society (ATS) describes asthma according to the following definition: "A condition with history of discrete attacks of wheezing, coughing or dyspnoea and increase in forced expiratory volume in one-second (FEV 1 ) of 20% from baseline after bronchodilator administration or decrease in FEV 1 of 20% after methacholine bronchoprovocation." 32 Since asthma and GERD are both common diseases, they often coexist. However, the coexistence of both disorders is far more frequent than by a sole chance association. [33] [34] [35] This observation led to the suggestion that there is a pathological link between the two diseases but data on the direction of causality, if any, are currently still lacking.
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| Prevalence of GERD in asthma
The prevalence of GERD in asthma patients is highly variable with estimates ranging from 30% to 90%. [36] [37] [38] [39] [40] Factors involved in this great variability are the small sample size on which study results are often based and the definition used for the diagnosis of asthma.
However, perhaps the most important reason for the observed variability is the detection method for GER and the thresholds used to determine increased GER.
Review of the available literature revealed that the average percentage of GERD prevalence in asthma based on symptoms alone or on pH-monitoring and endoscopy are 46.54% and 52.70%, respectively, whereas the estimate for control groups based on symptom evaluation is 23.59% ( Figure 1A ). Table 1 summarises the prevalence   of GERD in asthma patients, the information listed in this table is limited to studies including at least 50 patients.
In 2007, Havemann et al summarised the available data concerning GERD prevalence in patients with asthma based on 28 epidemiological studies. 36 They showed that the sample size weighted average prevalence of GERD symptoms (weekly heartburn and/or regurgitation) in asthma patients was 59.2%, whereas in control patients recruited from general medical clinics, it was 38.1%. In addition, the authors summarised that in patients with asthma the average prevalence of an abnormal oesophageal pH-profile, oesophagitis and hiatal hernia was 50.9%, 37.3% and 51.2%, respectively (pooled odds ratios:
5.5 (95% CI 1.9-15.8)). In general, abnormal distal oesophageal acid exposure has been shown in even up to 80% of asthma patients 37, 39 ( Table 1) . As mentioned previously, evidence of the direction of causality is lacking and several groups studied the prevalence of asthma in a population of GERD patients: the average prevalence of asthma in individuals with GERD was 4.6%, whereas in controls it was 3.9% (pooled odds ratios: 2.3 (95% CI 1.8-2.8)). 36 A large longitudinal study using data from the UK General practice research database showed that patients with asthma had an increased risk of developing GERD. However, this was not the case in the opposite direction:
patients with GERD had no increased risk of developing asthma. 41 The lack of an objective 24-hour pH-monitoring in several studies may have resulted in an underestimation in the prevalence of GERD, since "silent" reflux (GERD without any of the typical reflux symptoms) will not be picked up using questionnaires only.
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Another limitation is the absence of a healthy control group in several studies, or the inclusion of non-asthmatics with numerous other disorders such as allergic rhinitis; this may bias the interpretation of the results. 43, 44 Prevalence of silent reflux in asthmatics shows a wide variability ranging from 9.6% to 62%. 38, 45, 46 This variability can be explained by the different screening strategies for GERD.
Additional to the phenomenon of silent reflux, a study by Gisla- F I G U R E 1 Summary of data on prevalence of GERD in (A) asthma patients compared to controls and (B) COPD patients compared to controls. Prevalence was based on symptoms evaluated by questionnaires and endoscopy or pH-monitoring. Percentages are calculated from data of the literature described in Table 1 and Table 3 diagnosis and oesophageal adenocarcinoma (Odds Ratio 0.78, 95%
CI 0.396-1.68). 48 
| Mechanisms
Two main mechanisms have been suggested in the association between GERD and asthma: the 'reflux theory' as a direct and the 'reflex theory' as an indirect mechanism.
Reflux theory
The reflux theory refers to a direct mechanism by which microaspiration of (duodeno-) gastric contents causes damage to the pulmonary tree ( Figure 2A Only studies which included 50 patients or more were listed in this table. GER, gastro-oesophageal reflux; GERD, gastro-oesophageal reflux disease; ATS, american thoracic society; FSSG, frequency scale for symptoms of GERD; GINA, global strategy for asthma management.
One possible technique to detect pulmonary micro-aspiration of gastric contents is the measurement of pepsin and bile salts in broncho-alveolar lavage fluid (BALF) which is suggested to indicate aspiration of gastric contents. 54 The main limitation of using molecular showed an increase in total lung resistance after tracheal infusion of hydrochloric acid in cats. 56 Jack et al performed 24-hour oesophageal and tracheal pH-monitoring in four asthma patients with symptomatic GERD and 3 controls and showed a simultaneous fall in peak expiratory flow (PEF) with a tracheal pH-drop. 57 Pauwels et al demonstrated the presence of bile acids in sputum in 8/29 asthma patients (28%), suggesting aspiration of duodenogastric contents in a subgroup of asthma patients. Moreover, in patients with bile acid aspiration, the levels of bile acids were clearly associated with the degree of lung function impairment, suggesting the deleterious effect of micro-aspiration. 58 However, studies clarifying the exact role of micro-aspiration in humans are difficult to perform due to ethical reasons. Nevertheless, detection of pepsin and bile acids in sputum or in BALF has permitted an objective confirmation of micro-aspiration associated with GER.
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Reflex theory
In contrast to the reflux theory, the reflex theory describes an indirect mechanism in which distal oesophageal reflux stimulates the vagal nerve which in turn leads to bronchoconstriction ( Figure 2B ). A potential neural link between reflux and asthma might not be surprising since the oesophagus and tracheobronchial tree share an embryonic origin and therefore share the same neural innervation that may permit interaction. 20 This common innervation explains why stimuli in the distal oesophagus can lead to respiratory symptoms via vagally mediated reflexes.
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In a large group of asthma patients, percentages ranging from 46% to 78%, a relationship has been found between respiratory symptoms and oesophageal acidification due to acid reflux. These findings are in favour of the reflex theory. 37, 65 Furthermore, several studies demonstrated the occurrence of bronchoconstriction after distal oesophageal acid perfusion both in asthma as well as nonasthma patients (patients with normal lung function but with symptoms of dyspepsia and/or heartburn). [66] [67] [68] In 1994 However, not all literature data are consistent: Field and coworkers concluded that both spontaneous reflux and oesophageal acid perfusion had no or only a minimal effect on lung functions. 70 In addition, a study by Ekstr€ om et al showed that daytime instillation of oesophageal acid into the oesophagus (15 cm above LOS) did not induce clinically significant bronchospasm, respiratory symptoms or an increase in airway reactivity in patients with moderate to severe asthma and GERD (n = 8). Changes in FEV 1 in response to oesophageal acid stimulation on different occasions were small and not consistent in any of the patients. 71 An important limitation of the latter study however was the small sample size and the fact that no placebo group was included to compare the results of the oesophageal acid infusion. Nevertheless, these findings underline the uncertainty on how GER can worsen asthma symptoms without a clinically important change in lung function.
(A) (B)
F I G U R E 2 (A) Reflux theory: a direct mechanism by which micro-aspiration of (duodeno-) gastric contents can cause damage to the pulmonary tree. (B) Reflex theory: an indirect mechanism in which distal oesophageal reflux stimulates the vagal nerve which on its turn leads to bronchoconstriction 2. 78 Limitations of the study were the lack of a control group and the small sample size of only seven patients.
Taken together, the above-mentioned results suggest that oesophageal acidification might be an important contributing factor in the aggravation of asthma symptoms.
| Reflux -asthma -reflux?
Reflux and asthma have been closely linked to one and other, but an intriguing question remains unanswered: is GERD inducing asthma symptoms or is asthma causing GERD?
The high prevalence of GERD in asthmatics may at least partly shown to decrease LOS pressure, which potentially facilitates acid reflux. 21 On the contrary, several studies support the theory of refluxinduced asthma. GERD as the underlying cause of asthma symptoms is plausible in some cases, namely: onset of asthma symptoms in adulthood, no family history of asthma, no allergic component, heartburn and regurgitation before the onset of asthma symptoms, postprandial worsening of asthma symptoms and no response to traditional asthma medication. 21 In conclusion, it is obvious to state that a causal relationship between GERD and asthma is difficult to establish since GERD may induce bronchospasm and asthma on its turn may induce GERD.
| Treatment
Since a link between GERD and asthma has been considered, it can be expected that treatment of GERD in asthmatics could be useful.
It is suggested that other EOS of reflux such as hoarseness or cough might be helpful to predict in which patients with asthma and GERD, pulmonary function will improve when reflux is treated. 82, 83 In this paragraph, we will discuss different treatment modalities for GERD in patients with asthma.
Lifestyle changes
Lifestyle changes, such as smoking cessation, weight loss, dietary changes, head of bed elevation, avoidance of eating less than three hours before bed-time etc. can improve reflux control. 84 This improvement of oesophageal function could also be beneficial for bronchial symptoms in asthma patients, although there are no randomised-control trials to confirm this. Studies performed in the eighties [82] [83] 85 and early nineties 86 indicate that anti-reflux treatment with H 2 -receptor antagonists leads to an improvement in reflux symptoms and in some cases to improvement of nocturnal asthma symptoms (Table 2) . However, only small improvements in asthma control were found, and this was particularly true in patients with a history of GER. There was no evidence for improvement in lung function.
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Proton pump inhibitors | 181
with a definitive diagnosis of GERD had the highest improvement in morning PEF rate, but there were no statistically significant changes in FEV 1 when comparing PPI treatment with placebo (Table 2 ).
In 2003, Gibson et al performed a systematic review of 12 randomised, placebo-controlled trials in asthma patients using the Cochrane methodology, of which five trials investigated the effect of PPIs in patients with asthma. One study reported an increase in FEV 1 , one study reported a significant improvement in asthma symptoms and one study showed an improvement of nocturnal asthma after treatment with PPIs. 89 Chan and co-workers performed a meta-analysis summarising PPI treatment in asthma patients and concluded that there was In asthma patients with GERD, post-treatment reflux symptom score, pulmonary symptom score and night time asthma symptom score improved (P < .0001), and there was a significant increase of FEV 1 (P < .001). The authors conclude that PPI therapy improves nocturnal and daytime asthma symptoms in patients with asthma and concomitant GERD. In conclusion, there is insufficient evidence to recommend empirical use of PPIs in the treatment of asthma. 92, 94 However, PPI treatment might be useful in a subgroup of patients, in particular those with nocturnal asthma or nocturnal reflux as was shown in a study by Kiljander and coworkers. 95 
Anti-reflux surgery
Studies with H 2 -antagonists or PPIs have resulted in only minor improvements in pulmonary outcomes in asthmatics with GERD.
Anti-reflux surgery as treatment of GERD might be more efficient since it not only reduces oesophageal acid exposure but also has the potential to address the problem of ongoing non-acid reflux.
Anti-reflux surgery has been shown to not only improve symptoms typical for reflux disease, but also asthma symptom scores dropped and the consumption of asthma medication decreased (Table 2) . However, the effect of anti-reflux surgery on pulmonary function is not clear yet.
An early study by Perrin-Fayolle et al in 1989 showed improvement of pulmonary symptoms in 29/44 (66%) asthmatics with GERD more than 5 years after Nissen fundoplication. Pulmonary improvement rate appeared to be higher in patients with intrinsic asthma (no allergic component) and predominantly nocturnal asthma crises associated with reflux episodes. 96 In a study by Larrain et al, 6 months after an anti-reflux surgery, the use of asthma medication was significantly lower in 26 patients with non-allergic asthma and GER compared to 28 patients receiving placebo and this effect was sustained at long-term follow-up. 86 In 2000, a prospective study by Ekstr€ om and Johansson evaluated the effect of anti-reflux surgery (transabdominal or laparoscopic fundoplication) on 13 patients with severe GERD and asthma.
Although anti-reflux surgery appeared to have no effect on lung function, in the asthma group there was a small but non-significant reduction in asthma symptom scores and consumption of inhaled bronchodilators, or other regular asthma medication were lowered after anti-reflux surgery. Table 2) .
Silva et al analysed the efficacy of laparoscopic Nissen fundoplication in the remission of the EOS asthma in patients with GER. As expected, 6 months after surgery there was a significant reduction of heartburn. More importantly, there was a significant difference in daily crises of asthma 99 (Table 2 ).
Although the above-mentioned studies demonstrate that antireflux surgery can improve asthma symptom scores, the true beneficial effects of anti-reflux surgery on pulmonary function and the need for asthma medication remain unclear since most studies have several limitations: lack of a control group, poor documentation of asthma severity, no information if reflux was controlled postoperatively.
| Treatment strategy
There is increasing interest in identifying the impact of GERD on asthma development and therapy. Based on the literature, empiric therapy with PPIs is now considered the initial diagnostic step in patients suspected of having GERD-related symptoms. In those responsive to acid suppressive therapy, PPIs should be adjusted to 
| Summary
The interaction between asthma and GERD is complex, with a discrepancy between the high prevalence of GERD in asthma and the limited efficacy of anti-reflux therapy on asthma outcome. Results of anti-reflux therapy are conflicting: treatment seems to improve asthma symptoms but paradoxically lung function does not improve in the majority of patients. These disappointing results can be attributed to a wide variation in treatment possibilities of GERD such as H 2 -antagonists, PPI therapy, or anti-reflux surgery. Furthermore, variable study outcomes with similar treatment options can be due to differences in dosages and the duration of therapy periods. In the majority of the studies described above, treatment periods were often relatively short; it is conceivable that a longer observation period could be necessary before control of GER results in benefits for asthma-related symptoms. 89 Nevertheless, subgroups of asthmatics that may benefit from anti-reflux therapy have been identified, for example, patients with nocturnal reflux. Therefore, it is important to identify these particular subgroups, which can be achieved via 24-hour oesophageal pH-monitoring and/or pH-impedance monitoring. Oesophageal pH-monitoring is useful for the detection of patients with increased reflux and to evaluate a temporal relationship between reflux and respiratory symptoms (wheezing and cough). In addition to this, pH-impedance monitoring can help to identify patients with weakly acidic or nonacidic reflux.
| PART II: Chronic obstructive pulmonary disease
According to the 'Global initiative for chronic obstructive lung disease' (GOLD) -diagnosis of chronic obstructive pulmonary disease (COPD) is defined as follows: "Chronic obstructive pulmonary disease, a common preventable and treatable disease, is characterised by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. Exacerbations and comorbidities contribute to the overall severity in individual patients". 101 COPD is associated with several comorbidities, for example, cardiovascular diseases, sleep apnoea syndrome, dyslipidaemia, diabetes and also GERD. 102, 103 The association between GERD and COPD has been under investigation for many years; however, the impact of GERD on COPD-related health status remains questionable.
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| Prevalence of GERD in COPD
Similar to the prevalence of GERD in asthma patients, the rates of GERD in COPD are highly variable. Based on the results of selfreport questionnaires, the prevalence of GERD in patients with COPD ranges from 19% to 29%, with an average of 24.40% 44, 105, [107] [108] [109] (Table 3 , Figure 1B ). This variation is partially due to the heterogeneity of the questionnaire used. In control groups, the average percentage of GERD prevalence is 18.97% based on symptoms evaluated by questionnaires. On the other hand, when using objective reflux measurements (such as 24-hour oesophageal pH-monitoring), the prevalence of GERD in COPD ranges from 19% to 78% (average 42.80%) compared to 18.50% in control groups (Table 3 , Figure 1B ). Variability can be explained by whether the test was undertaken while patients were on or off anti-reflux medication and the difference in criteria to define the presence of GERD.
Using the UK general practice research database, Garcia Rodriguez et al identified a cohort of patients with a first diagnosis of GERD (n = 4391, control cohort without GERD diagnosis n = 5118) and a second cohort of patients with a first diagnosis of COPD (n = 1628, control cohort without COPD diagnosis n = 14 243). To study the incidence of a GERD diagnosis among the patients with COPD, and of a COPD diagnosis among the patients with GERD, both groups were compared to their control cohorts. During a 5-year follow-up, the relative risk of an incident COPD diagnosis in patients with GERD was 1.17 (95% CI, 0.91-1.49), while the relative risk of an incident GERD diagnosis among patients with COPD was 1.46 (95% CI, 1.19-1.78). The authors conclude that patients with a diagnosis of COPD are at a significantly increased risk of a diagnosis of GERD compared to individuals without COPD diagnosis. 110 Recently, GERD was reported by 29% of 4483 COPD patients, with a female predominance, and subjects with GERD were more likely to have chronic bronchitis symptoms; they had more severe dyspnoea and poorer quality of life scores. A significant relationship was detected between GERD and frequent exacerbations at baseline (≥2 exacerbations per year at inclusion odds ratio: 1.40, P = .006). 105 In addition, several smaller studies similarly showed a higher frequency of GERD in COPD patients compared to individuals without COPD with an overall prevalence ranging from 30% to 78%. 111, 118, [119] [120] [121] [122] In summary, it has been shown that the occurrence of GERD is more frequent in COPD patients compared to a control population without COPD. The presence of GERD in COPD appeared to be associated with increased pulmonary symptoms, a poorer quality of life and an increased frequency of COPD exacerbations. In patients with severe COPD, a higher prevalence of asymptomatic GER was detected. Since silent reflux is relatively frequent in patients with COPD (16%-74%) an objective confirmation of the presence of GERD is very important. [112] [113] [114] There are currently no data available on the prevalence and/or the association of Barrett's oesophagus and COPD.
| Mechanisms
The mechanisms underlying a relationship between reflux and asthma, as described earlier, can be extrapolated to patients with COPD: similar to asthma, micro-aspiration of gastric contents or bronchospasm induced by stimulation of the vagal nerve due to the irritation of the oesophagus might contribute to the association between GERD and pulmonary disease. 115 COPD patients may be particularly vulnerable to GERD since an increased intra-abdominal pressure and negative intra-thoracic pressure, increased frequency of cough and use of b 2 -agonists can aggravate reflux and are common in these patients.
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Reflux theory
As discussed in previous paragraphs, GER and particularly GER with a high proximal extent, is a risk factor for micro-aspiration and this may cause damage to the pulmonary tree. Micro-aspiration can be measured by molecular markers such as pepsin and bile salts in sputum/BALF. In addition, as described in a review by Sweet et al the risk of aspiration can be predicted by proximal oesophageal acid detection by dual pH-monitoring, nevertheless even one single reflux episode can lead to aspiration. Unfortunately, the authors did not explore a correlation between increasing concentrations of pepsin in sputum and severity of lung disease. (Table 4) . Exacerbations are described as critical events in the natural history and management of the disease because they are related to the worsening of quality of life, accelerated decline in lung function, hospital admissions, a high use of health care resources and even increased risk of death. 114, 115, 119 Data in the literature not only suggest that GERD is more common in patients with COPD, but it is also a risk factor for COPD exacerbations and predicts a higher risk for the so called 'frequent exacerbator'-phenotype.
Rascon-Aguilar et al found that the rate of COPD exacerbations was twice as high in a group of GERD positive COPD patients compared to a GERD negative group 120 ( (Table 4) . 121 Takada et al evaluated 221 patients with stable COPD for the presence of GERD and showed that the mean number of acute exacerbations of COPD during 1 year and the number of hospitalisations due to acute exacerbations of COPD were significantly higher in patients with GERD compared to those without GERD (Table 4 ). The authors concluded that GERD increased the frequency of acute exacerbations of COPD and hospitalisation due to acute exacerbations of COPD. The presence of GERD is therefore suggested to be a predictive factor for hospitalisation due to COPD exacerbation. 122 In a retrospective study, Rogha et al included 110 patients diagnosed with COPD based on clinical features and pulmonary function tests. A little over half of the patients (53.6%) were GERD positive (questionnaire based) and experienced significantly more acute exacerbations of COPD compared to GERD negative patients (P < .001).
Moreover, the rate of hospitalisation due to COPD exacerbations was significantly higher in GERD positive patients (P < .05). (Table 4 ). The effect of PPI use was analysed but did not change the association between GERD and COPD exacerbation. 105 Tsai et al evaluated 1210 COPD patients who were diagnosed with GERD and were taking GERD-related medication (PPI or H 2 -receptor antagonists) and 2420 COPD patients without GERD. After 12 months of follow-up, COPD patients with GERD had more hospitalisations per 1000 person-months compared to COPD patients without GERD. GERD was found to be an independent predicator of hospitalisation. The investigators showed a significantly higher incidence rate and independently increased risk of hospitalisations among COPD patients who subsequently developed GERD during the first year following their COPD diagnosis than COPD patients who did not develop GERD. 125 
| Treatment
Data concerning the effects of anti-reflux treatment on pulmonary function in COPD patients are still limited. In the only study examining an H 2 -receptor antagonist, it was shown that acute administration of ranitidine led to a decrease in FVC and FEV 1 in patients with COPD (Table 5) . 126 Similarly, the role for PPIs in the treatment of COPD patients remains to be elucidated. Several studies demonstrate an improvement in COPD symptoms and a decrease in the number of exacerbations of COPD after treatment with PPIs.
However, other studies suggest the opposite, with patients using
PPIs having a higher number of exacerbations of COPD.
Eryuksel et al investigated the effect of a 2-month treatment with pantoprazole (40 mg/day) in 13 COPD patients with laryngopharyngeal reflux and found a significant improvement in COPD symptoms (P < .01) as well as in laryngopharyngeal reflux symptoms (P < .01) and laryngeal examination score (P < .0001) ( Table 5 ).
Although the treatment group was rather small and the study was not placebo-controlled, authors concluded that treatment of laryngopharyngeal reflux resulted in a significant improvement in the symptoms of COPD. 127 Sasaki et al enrolled 100 patients with COPD without GERD and randomly assigned them into two groups: (1) conventional COPD therapy ( = control group) or (2) conventional COPD therapy combined with PPI treatment (lansoprazole, 15 mg/day). The authors found that the number of COPD exacerbations per person in 1 year in the PPI treatment group was significantly lower compared to the control group (P < .001). 128 The results of this study should be interpreted with caution, since it was a single-blind, non-placebo-controlled trial.
In their cohort of 2135 COPD patients, Benson et al found that both GERD and the use of acid suppressive medication (PPI and/or H 2 -receptor antagonists) at baseline were associated with a 20% to 60% increased risk of moderate-severe exacerbations and hospitalised exacerbations during the 3 years of follow-up, thereby questioning the role of acid suppressive therapy in CODP. 108 On the other hand, Ingebrigtsen et al described that presence of GERD was associated with an increased risk of COPD exacerbation, but only in those patients who did not use acid suppressive treatment regularly.
Individuals with GERD, using acid suppressive therapy regularly did not have an increased risk of exacerbations (Table 5) . 129 To conclude, several studies indicate that PPI treatment might be beneficial to COPD patients, however, other studies imply that PPI use might have an adverse effect on pulmonary function (Table 5) . | 187 search showed that nocturnal reflux, non-allergic asthma, new onset asthma in adulthood and the presence of typical reflux symptoms are the best predictors for a favourable outcome of acid suppressive therapy in patients with asthma. In patients with COPD, there is a link between the rate of exacerbations and the presence of GERD, but causality still needs to be proven. Nevertheless, it is important to define particular subgroups of asthmatics and COPD patients that may benefit from anti-reflux therapy (eg, patients with nocturnal or silent reflux). There is a clear need for objective methods for diagnostic confirmation of GERD in patients suffering from COPD or asthma. In addition, there is a need for well-designed large GERD treatment follow-up studies in these conditions.
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